Page 117 - Read Online

McKenna et al Hypoxia in prostate cancer

activated inhibitor of DNA dependent protein kinase. EJC O’Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ,
Supplements 2010;8:161-2. Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D,
50. Gani C, Coackley C, Kumareswaran R, Schutze C, Krause M, Wagstaff J, Parmar MK; STAMPEDE investigators. Addition of
Zafarana G, Bristow RG. In vivo studies of the PARP inhibitor, AZD- docetaxel, zoledronic acid, or both to first-line long-term hormone
2281, in combination with fractionated radiotherapy: an exploration therapy in prostate cancer (STAMPEDE): survival results from an
of the therapeutic ratio. Radiother Oncol 2015;116:486-94. adaptive, multiarm, multistage, platform randomised controlled trial.
51. Jiang Y, Verbiest T, Devery AM, Bokobza SM, Weber AM, Lancet 2016;387:1163-77.
Leszczynska KB, Hammond EM, Ryan AJ. Hypoxia potentiates 63. Li F, Joergensen JT, Hansen AE, Kjaer A. Kinetic modeling in PET
the radiation-sensitizing effect of olaparib in human non-small cell imaging of hypoxia. Am J Nucl Med Mol Imaging 2014;4:490-506.
lung cancer xenografts by contextual synthetic lethality. Int J Radiat 64. White NS, Errington RJ. Fluorescence techniques for drug delivery
Oncol Biol Phys 2016;95:772-81. research: theory and practice. Adv Drug Deliv Rev 2005;57:17-42.
52. Mistry IN, Thomas M, Calder EDD, Conway SJ, Hammond EM. 65. Errington RJ, Ameer-Beg SM, Vojnovic B, Patterson LH, Zloh M,
Clinical advances of hypoxia-activated prodrugs in combination with Smith PJ. Advanced microscopy solutions for monitoring the kinetics
radiation therapy. Int J Radiat Oncol Biol Phys 2017;98:1183-96. and dynamics of drug-DNA targeting in living cells. Adv Drug Deliv
53. Barreto-Andrade JC, Efimova EV, Mauceri HJ, Beckett MA, Sutton Rev 2005;57:153-67.
HG, Darga TE, Vokes EE, Posner MC, Kron SJ, Weichselbaum RR. 66. Feng L, Cheng L, Dong Z, Tao D, Barnhart TE, Cai W, Chen M, Liu Z.
Response of human prostate cancer cells and tumors to combining Theranostic liposomes with hypoxia-activated prodrug to effectively
PARP inhibition with ionizing radiation. Mol Cancer Ther destruct hypoxic tumors post-photodynamic therapy. ACS Nano
2011;10:1185-93. 2017;11:927-37.
54. Patterson LH. Bioreductively activated antitumor N-oxides: the 67. Williams KJ, Albertella MR, Fitzpatrick B, Loadman PM, Shnyder
case of AQ4N, a unique approach to hypoxia-activated cancer SD, Chinje EC, Telfer BA, Dunk CR, Harris PA, Stratford IJ. In vivo
chemotherapy. Drug Metab Rev 2002;34:581-92. activation of the hypoxia-targeted cytotoxin AQ4N in human tumor
55. Nesbitt H, Byrne NM, Williams SN, Ming L, Worthington J, xenografts. Mol Cancer Ther 2009;8:3266-75.
Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ. 68. Yang KS, Kohler RH, Landon M, Giedt R, Weissleder R. Single
Targeting hypoxic prostate tumors using the novel hypoxia-activated cell resolution in vivo imaging of DNA damage following PARP
prodrug OCT1002 inhibits expression of genes associated with inhibition. Sci Rep 2015;5:10129.
malignant progression. Clin Cancer Res 2017;23:1797-808. 69. Polanski R, Vincent J, Polanska UM, Petreus T, Tang EK. Caspase-8
56. Pors K, Shnyder SD, Teesdale-Spittle PH, Hartley JA, Zloh M, activation by TRAIL monotherapy predicts responses to IAPi and
Searcey M, Patterson LH. Synthesis of DNA-directed pyrrolidinyl TRAIL combination treatment in breast cancer cell lines. Cell Death
and piperidinyl confined alkylating chloroalkylaminoanthraquinones: Dis 2015;6:e1893.
Potential for development of tumor-selective N-oxides. J Med Chem 70. Fricke T, Mart RJ, Watkins CL, Wiltshire M, Errington RJ, Smith
2006;49:7013-23. PJ, Jones AT, Allemann RK. Chemical synthesis of cell-permeable
57. Ming L, Byrne NM, Camac SN, Mitchell CA, Ward C, Waugh DJ, apoptotic peptides from in vivo produced proteins. Bioconjug Chem
McKeown SR, Worthington J. Androgen deprivation results in time- 2011;22:1763-7.
dependent hypoxia in LNCaP prostate tumours: Informed scheduling 71. Mart RJ, Errington RJ, Watkins CL, Chappell SC, Wiltshire M,
of the bioreductive drug AQ4N improves treatment response. Int J Jones AT, Smith PJ, Allemann RK. BH3 helix-derived biophotonic
Cancer 2013;132:1323-32. nanoswitches regulate cytochrome c release in permeabilised cells.
58. Wade D. Deuterium isotope effects on noncovalent interactions Mol Biosyst 2013;9:2597-603.
between molecules. Chem Biol Interact 1999;117:191-217. 72. Del Gaizo Moore V, Letai A. BH3 profiling--measuring integrated
59. Alonzi R, Padhani AR, Taylor NJ, Collins DJ, D’Arcy JA, Stirling function of the mitochondrial apoptotic pathway to predict cell fate
JJ, Saunders MI, Hoskin PJ. Antivascular effects of neoadjuvant decisions. Cancer Lett 2013;332:202-5.
androgen deprivation for prostate cancer: an in vivo human study 73. Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M,
using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Aprikian A, Armenia J, Arora A, Auman JT, Balasundaram M, Balu S,
Biol Phys 2011;80:721-7. Barbieri CE, Bauer T, Benz CC, Bergeron A, Beroukhim R, Berrios
60. Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T, M, Bivol A, Bodenheimer T, Boice L, Bootwalla MS, dos Reis RB,
Warde P, Catton C, Menard C, Bayley A, Gospodarowicz M, Hill R. Boutros PC, Bowen J, Bowlby R, Boyd J, Bradley RK, Breggia A,
Androgen withdrawal in patients reduces prostate cancer hypoxia: Brimo F, Bristow CA, Brooks D, Broom BM, Bryce AH, Bubley G,
Implications for disease progression and radiation response. Cancer Burks E, Butterfield YSN, Button M, Canes D, Carlotti CG, Carlsen
Res 2007;67:6022-5. R, Carmel M, Carroll PR, Carter SL, Cartun R, Carver BS, Chan
61. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger JM, Chang MT, Chen Y, Cherniack AD, Chevalier S, Chin L, Cho
M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang J, Chu A, Chuah E, Chudamani S, Cibulskis K, Ciriello G, Clarke
NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. A, Cooperberg MR, Corcoran NM, Costello AJ, Cowan J, Crain D,
Chemohormonal therapy in metastatic hormone-sensitive prostate Curley E, David K, Demchok JA, Demichelis F, Dhalla N, Dhir R,
cancer. N Engl J Med 2015;373:737-46. Doueik A, Drake B, Dvinge H, Dyakova N, Felau I, Ferguson ML,
62. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Frazer S, Freedland S, Fu Y, Gabriel SB, Gao JJ, Gardner J, Gastier-
Spears MR, Ritchie AWS, Parker CC, Russell JM, Attard G, de Bono Foster JM, Gehlenborg N, Gerken M, Gerstein MB, Getz G, Godwin
J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, AK, Gopalan A, Graefen M, Graim K, Gribbin T, Guin R, Gupta M,
Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti Hadjipanayis A, Haider S, Hamel L, Hayes DN, Heiman DI, Hess J,
P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hoadley KA, Holbrook AH, Holt RA, Holway A, Hovens CM, Hoyle
Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, AP, Huang M, Hutter CM, Ittmann M, Iype L, Jefferys SR, Jones

Journal of Cancer Metastasis and Treatment ¦ Volume 4 ¦ March 1, 2018 11